We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
-22.69%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$809M
AUM Growth
-$91.8M
Cap. Flow
+$168M
Cap. Flow %
20.82%
Top 10 Hldgs %
80.44%
Holding
30
New
6
Increased
6
Reduced
4
Closed
6

Top Buys

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$62.2M
2
DBVT
DBV Technologies
DBVT
+$48.3M
3
ONC
BeOne Medicines Ltd
ONC
+$35.8M
4
QURE icon
uniQure
QURE
+$33.4M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$26.2M

Top Sells

Rank Stock Value
1
MDCO
Medicines Co
MDCO
+$27.2M
2
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$21.4M
3
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$18.4M
4
ESPR
Esperion Therapeutics
ESPR
+$8.43M
5
RIGL icon
Rigel Pharmaceuticals
RIGL
+$7.45M

Sector Composition

Rank Sector Weight
1 Healthcare 96.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONC
1
BeOne Medicines Ltd
ONC
$32.8B
$126M 15.6%
900,000
+270,000
+43% +$35.8M
SLDB icon
2
Solid Biosciences
SLDB
$794M
$93.8M 11.58%
233,218
+41,111
+21% +$19.3M
PTCT icon
3
PTC Therapeutics
PTCT
$5.68B
$74M 9.14%
2,155,000
– –
WVE icon
4
Wave Life Sciences
WVE
$1.09B
$69.4M 8.57%
1,650,000
+59,400
+4% +$2.64M
MRTX
5
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$66.4M 8.21%
1,565,560
– –
ICPT
6
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$60.5M 7.47%
+600,000
New +$62.2M
ESPR
7
DELISTED
Esperion Therapeutics
ESPR
$55.2M 6.82%
1,200,000
-175,000
-13% -$8.43M
ODT
8
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$41.9M 5.18%
2,978,762
+151,824
+5% +$2.36M
QURE icon
9
uniQure
QURE
$3.03B
$34.6M 4.27%
+1,200,000
New +$33.4M
RCKT icon
10
Rocket Pharmaceuticals
RCKT
$340M
$29.1M 3.6%
1,966,051
– –
DBVT
11
DBV Technologies
DBVT
$799M
$28.9M 3.57%
450,000
+300,000
+200% +$48.3M
GBT
12
DELISTED
Global Blood Therapeutics, Inc.
GBT
$28.7M 3.55%
+700,000
New +$26.2M
AMRN
13
Amarin Corp
AMRN
$299M
$20.4M 2.52%
75,000
+10,000
+15% +$3.65M
CBAY
14
DELISTED
Cymabay Therapeutics
CBAY
$16.5M 2.04%
2,094,000
– –
IMMU
15
DELISTED
Immunomedics Inc
IMMU
$16.4M 2.03%
+1,150,000
New +$22.8M
KURA icon
16
Kura Oncology
KURA
$800M
$11.9M 1.47%
844,789
– –
KNSA icon
17
Kiniksa Pharmaceuticals
KNSA
$5.8B
$8.16M 1.01%
290,577
-882,123
-75% -$18.4M
LITS
18
Lite Strategy Inc
LITS
$32.8M
$7.69M 0.95%
145,655
– –
ESPR
19
CALL
DELISTED
Esperion Therapeutics
ESPR
$4.6M 0.57%
+100,000
New +$4.82M
MDCO
20
DELISTED
Medicines Co
MDCO
$4.44M 0.55%
232,000
-1,168,000
-83% -$27.2M
KALV
21
DELISTED
KalVista Pharmaceuticals
KALV
$3.95M 0.49%
200,000
– –
MTNB icon
22
Matinas BioPharma
MTNB
$1.88M
$3.36M 0.41%
+112,857
New +$4.43M
RETA
23
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$2.81M 0.35%
50,000
-350,000
-88% -$21.4M
ELDN icon
24
Eledon Pharmaceuticals
ELDN
$261M
$519K 0.06%
18,021
– –
RGLS
25
DELISTED
Regulus Therapeutics
RGLS
– –
-14,148
Closed -$4.03M
1
2

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q4 2018 Portfolio in Review

As of Q4 2018, Boxer Capital held 30 positions worth $809M, down 10% from $901M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Boxer Capital deployed $168M of net new capital in Q4 2018, opening 6 new positions and adding to 6 existing holdings. Its largest new stake was Intercept Pharmaceuticals, Inc.: 600,000 shares worth $60.5M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier.

On the sell side, the largest reduction was Medicines Co, an estimated $27.2M trimmed.

  • Boxer Capital's largest Q4 2018 buy was Intercept Pharmaceuticals, Inc.: 600,000 shares worth $60.5M.
  • Boxer Capital added most to DBV Technologies in Q4 2018, an estimated $48.3M increase.
  • Boxer Capital's biggest Q4 2018 reduction was Medicines Co, cutting an estimated $27.2M.
  • Boxer Capital fully exited Rigel Pharmaceuticals in Q4 2018, selling an estimated $7.45M.
  • Boxer Capital's ten largest holdings make up 80% of its $809M portfolio in Q4 2018.
  • Boxer Capital opened 6 new positions and closed 6 in Q4 2018.
  • Boxer Capital's portfolio value fell 10% quarter-over-quarter to $809M.

Based on Boxer Capital's 13F filing for Q4 2018, filed 14 Feb 2019.